What's Hot
View all perspectives
Angus Worthing MD AngusWorthing
4 years ago
Today's #ACR20 lecture @r_burmester shows the biologic revolution was a result of serendipity -- this will spark the long-awaited new & improved name of our profession: serendipitology! Hi I'm Dr. Worthing I'm a Serendipitologist. I use drugs intended for infections, cancer etc.! https://t.co/buDqwAVK9u
Mohammad A. Ursani MD, RhMSUS DrMAUrsani
4 years ago
Dr Joan Merrill presents a phase 2 trial
use of Iberdomide in patients with #SLE
-Novel MOA —> blocks TF Ailos and Ikaros
Conclusion
-Primary end point was met at week 24
-Effects greater in Aiolos high/Type 2 IFN high
-Iverdomdie was tolerated well
#Lupus
#ACR20
#ACRambassador https://t.co/zpQR9ceV7p
Emily Littlejohn ELittlejohnDO
4 years ago
We need to start utilizing and normalizing anti phosphatidylserine/prothrombin antibody ordering in clinical practice #ACR20 https://t.co/LeeHnuX9x0
E. Sloan esloanmd
4 years ago
Nice succinct review of recent DOAC studies in #APS by Dr. Ortel. Recommends avoiding DOACs in triple positive pts #antiphospholipid #ACR20 https://t.co/Hc6ye3mvTg
The Lancet Rheumatology TheLancetRheum
4 years ago
Editors Pick for #ACR20—Leflunomide–hydroxychloroquine combination therapy in patients with primary Sjögren's syndrome (RepurpSS-I): a placebo-controlled, double-blinded, randomised clinical trial https://t.co/cunDxVl5XG https://t.co/OGItXCuWDI
Mohammad A. Ursani MD, RhMSUS DrMAUrsani
4 years ago
Dr Richard Furie-> Obinutuzumab for proliferative #lupus nephritis
-Compared to rituximab, has more B-cell depletion in tissue and #SLE patients
-Meaningful benefits over SOC alone on renal response through week 104.
-Phase 3 REGENCY pending.
#ACR20
#ACRambassador
#Rheumatology https://t.co/aPi1yueAiV
Dr. John Cush RheumNow
4 years ago
Rheumatoid arthritis and lung disease in the spotlight at #ACR20 by @jeffsparks
https://t.co/0Dth0k6uve https://t.co/pGfGtq8Sz7
Combination therapy with biologic and conventional DMARDs can be highly effective at inducing remission in patients with RA. Once controlled, patients are often interested in stopping combination drug therapy due to concerns related to medication burdens, side effect profiles, or safety.
Richard Conway RichardPAConway
4 years ago
After the SEAM-RA study, in patients taking MTX and ETN in sustained remission would you? #ACR20 @rheumnow
Mrinalini Dey DrMiniDey
4 years ago
Thanks @EBRheum for a great rundown of how to keep up with the #rheumatology literature- particularly liked the reminder to use tech & @Twitter as well as reading.
"#RheumTwitter is fun, it's collaborative, it's full of doughnuts."
Proud to be a rheum trainee!😄
#ACR20 @RheumNow https://t.co/V1zaUD1KCJ
David Liew drdavidliew
4 years ago
Should ARBs be adjunct Rx in GCA?
Plausible target:
- previous pharmacoepi
- ATII expressed in GCA inflamm lesions
- ATII induced pro-inflamm in PBMC/co-cultured VSMC
- steroids modulate ATII expression in GCA TA ex vivo
Maybe worth testing?
Cid et al #ACR20 ABST0510 @RheumNow https://t.co/mNNzZVYe7g
Olga Petryna DrPetryna
4 years ago
@RheumNow #acr20 abs0622 infection induced MPO anca vasc: most common triggers viruses(35.2%), mycobacterial (29.4%)& bacterial inf (29.4%). Onset 3 mo post inf. (70.5%) renal involvement, w/ biopsy-proven GN in 53%. 17.6%died. Rx steroids+abx, CYC in 47%.
k dao KDAO2011
4 years ago
We have great options all around! Both are efficacious in biologic (TNFi) failures for RA patients.
Comparative Clinical Efficacy of Sarilumab versus Upadacitinib over 12 Weeks: Matching-Adjusted Indirect Comparison Analysis Abst#0827 #ACR20 @RheumNow
https://t.co/1SsL9qLJD3
Robert B Chao, MD doctorRBC
4 years ago
EQUATOR2 52wk extension trial - Filgotinib on enthesitis in PsA pts
1️⃣Clinical resolution of enthesitis at 52wks 77% by LEI and SPARCC
2️⃣Pts who did not respond by wk 16➡️77% and 81% resolution enthesitis by LEI and SPARCC
@RheumNow #ACR20 Abs#0910 https://t.co/mCe32rrAcc
Poster Hall